A Daily GLP 1 Pill Could Curb Heavy Drinking The recent trial on semaglutide, an active ingredient in popular diabetes medications Ozempic and Wegovy, has yielded promising results in reducing heavy drinking among individuals with alcohol use disorder.
This study's findings suggest that GLP 1s could have a broader application beyond treating type 2 diabetes. Researchers have been exploring the potential of GLP 1 therapy as an addiction treatment for several years.
Observational studies have hinted at its effectiveness in reducing symptoms of various addictions, including alcohol use disorder. However, conclusive evidence from clinical trials has only just begun to emerge.